OLINDA/EXM 2.0 Recommended Radiation Dose Estimates for 18F-FDG: Female Data
| Site | Adult | 15-y-old | 10-y-old | 5-y-old | 1-y-old |
| Adrenals | 1.51E-02 | 1.62E-02 | 2.43E-02 | 3.76E-02 | 6.68E-02 |
| Brain | 3.96E-02 | 3.91E-02 | 4.25E-02 | 4.58E-02 | 5.79E-02 |
| Breasts | 1.01E-02 | 1.09E-02 | —– | —– | —– |
| Esophagus | 1.54E-02 | 1.75E-02 | 2.71E-02 | 4.31E-02 | 7.81E-02 |
| Eyes | 1.29E-02 | 1.41E-02 | 2.00E-02 | 3.02E-02 | 5.00E-02 |
| Gallbladder wall | 1.43E-02 | 1.52E-02 | 2.32E-02 | 3.40E-02 | 5.92E-02 |
| Left colon | 1.55E-02 | 1.57E-02 | 2.47E-02 | 3.88E-02 | 6.71E-02 |
| Small intestine | 1.38E-02 | 1.57E-02 | 2.43E-02 | 3.82E-02 | 6.68E-02 |
| Stomach wall | 1.38E-02 | 1.42E-02 | 2.14E-02 | 3.39E-02 | 5.95E-02 |
| Right colon | 1.43E-02 | 1.48E-02 | 2.28E-02 | 3.57E-02 | 6.07E-02 |
| Rectum | 2.56E-02 | 3.09E-02 | 4.31E-02 | 6.23E-02 | 9.65E-02 |
| Heart wall | 8.21E-02 | 9.18E-02 | 1.90E-01 | 2.23E-01 | 2.11E-01 |
| Kidneys | 1.30E-02 | 1.38E-02 | 2.09E-02 | 3.39E-02 | 6.01E-02 |
| Liver | 2.71E-02 | 2.84E-02 | 4.19E-02 | 6.03E-02 | 1.01E-01 |
| Lungs | 2.21E-02 | 2.59E-02 | 3.73E-02 | 5.86E-02 | 1.10E-01 |
| Ovaries | 1.82E-02 | 2.08E-02 | 2.84E-02 | 5.04E-02 | 8.67E-02 |
| Pancreas | 1.51E-02 | 1.60E-02 | 2.45E-02 | 3.81E-02 | 6.72E-02 |
| Salivary glands | 1.29E-02 | 1.47E-02 | 2.21E-02 | 3.33E-02 | 5.75E-02 |
| Red marrow | 1.23E-02 | 1.23E-02 | 1.49E-02 | 2.05E-02 | 3.53E-02 |
| Osteogenic cells | 1.08E-02 | 1.08E-02 | 1.20E-02 | 1.36E-02 | 1.90E-02 |
| Spleen | 1.26E-02 | 1.34E-02 | 2.02E-02 | 3.31E-02 | 5.92E-02 |
| Thymus | 1.58E-02 | 1.68E-02 | 2.50E-02 | 3.81E-02 | 6.64E-02 |
| Thyroid | 1.15E-02 | 1.33E-02 | 2.07E-02 | 3.34E-02 | 5.96E-02 |
| Urinary bladder wall | 1.56E-01 | 1.58E-01 | 2.35E-01 | 3.65E-01 | 6.01E-01 |
| Uterus | 2.59E-02 | 3.24E-02 | 5.27E-02 | 7.52E-02 | 1.13E-01 |
| Total body | 1.41E-02 | 1.40E-02 | 2.20E-02 | 3.50E-02 | 6.41E-02 |
Data are in mSv/MBq (biokinetic data: ICRP 128–recommended model; physical models: RADAR ICRP 89 reference phantom series; effective doses: ICRP 103 weighting factors).